Operational RecoveryArtivion is recovering well from the previous cyber-attack, with its tissue business sales ramping back up, positioning the company for acceleration and recovery.
Regulatory ChallengesEndospan expects to submit its PMA to the FDA after 12-month data from the trial is available, putting it on track for FDA approval in late 2026.
Stock DependencyThe company launched AMDS under HDE, which carries a strong initial stocking benefit, and most of the revenue thus far has been from stocking, according to the company.